COMMUNIQUÉS West-GlobeNewswire

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment

16/01/2025 - 14:30

FemaSeed ® patent application provides additional coverage for Femasys’ therapeutic option for women seeking infertility solution ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading [...]

FOXO TECHNOLOGIES INC., CONFIRMS DETAILS OF SPECIAL MEETING OF SHAREHOLDERS ON JANUARY 17, 2025.

16/01/2025 - 14:30

MINNEAPOLIS, MN, Jan. 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold its previously announced Special Meeting of its Shareholders at 10:30 am EST on Friday [...]

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer

16/01/2025 - 14:19

- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer - Prostate Cancer: The Second Most Common Cancer in Men Globally IRVINE, Calif., Jan. 16, 2025 (GLOBE [...]

Carmell Announces Closing of Elevai Skincare Acquisition

16/01/2025 - 14:00

PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of [...]

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

16/01/2025 - 14:00

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for [...]

Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development

16/01/2025 - 14:00

Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply VALENCIA, Calif. [...]

Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

16/01/2025 - 14:00

Initial plans target European clinical trials while providing standard testing to clinicians for individual patients There are an estimated 250,000 gynecologic cancers diagnosed annually across Europe PITTSBURGH, Jan. [...]

Inteleos Foundation Announces 2025 MedMissions Award to Advance Ultrasound Access in Four Nations

16/01/2025 - 14:00

ROCKVILLE, Md., Jan. 16, 2025 (GLOBE NEWSWIRE) -- The Inteleos Foundation, a global health nonprofit organization, has announced the selection of three recipients of the annual MedMissions Award, designed to advance [...]

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

16/01/2025 - 14:00

Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued [...]

NOTICE TO DISREGARD -- King Faisal Specialist Hospital & Research Centre

16/01/2025 - 13:46

RIYADH, Saudia Arabia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- We are advised by King Faisal Specialist Hospital & Research Centre that journalists and other readers should disregard the news release, “KFSH&RC [...]

Samsung Bioepis Releases First Quarter 2025 US Biosimilar Market Report

16/01/2025 - 13:30

Marks the Third Year Since the Launch of the First US Biosimilar Market Report INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market [...]

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

16/01/2025 - 13:30

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, [...]

Avicanna Announces Scientific and Medical Affairs Collaboration with Vectura Fertin Pharma

16/01/2025 - 13:30

Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ”) (TSX: AVCN) ( [...]

The Joint Corp. Reports 2024 Operating Metrics

16/01/2025 - 13:05

- Adjustments Performed in 2024 Grows 9%, Compared to 2023 - - Receives Letters of Intent for the majority of the Corporate Portfolio in Early January 2025 - SCOTTSDALE, Ariz., Jan. 16, 2025 (GLOBE NEWSWIRE) -- The [...]

Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers

16/01/2025 - 13:00

Meaningful tumor shrinkage observed in five out of 10 patients with partial and minor responses and 90% disease control rate in patients with salivary gland cancers Phase 1b expansion cohorts screening patients in [...]

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

16/01/2025 - 13:00

WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

16/01/2025 - 13:00

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment [...]

Micron Biomedical Extends Series A Financing to 33+ Million to Accelerate Commercialization of Needle-Free Therapeutics and Vaccines

16/01/2025 - 13:00

$16M extension round led by J2 Ventures and GHIC builds on support from BARDA, CEPI, the Bill & Melinda Gates Foundation and others to simplify access to life-saving drugs ATLANTA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- [...]

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

16/01/2025 - 12:00

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeks BLA resubmission on track for calendar Q1 2025 Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in [...]